OPEN END TURBO OPTIONSSCHEIN - EDWARDS LIFESCIENCES | Real-time Bid/Ask 11:57:03 20/06/2024 BST | ||
| 0.92 EUR / 0.98 EUR | +1.06% |
|
| Current month | -11.32% | ||
| 1 month | +10.59% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 0.93 | -1.06% |
| 19/06/24 | 0.94 | +4.44% |
| 18/06/24 | 0.9 | -15.89% |
| 17/06/24 | 1.07 | +0.94% |
| 14/06/24 | 1.06 | +3.92% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 08:43 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JQ46EL |
| ISIN | DE000JQ46EL4 |
| Date issued | 25/08/2022 |
| Strike | 98.27 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.52 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.46 € |
|---|---|
| Lowest since issue | 0.18 € |
| Spread | 0.06 € |
| Spread % | 6.12% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
88.52
USD
Average target price
96.05
USD
Spread / Average Target
+8.51%
- Stock Market
- Certificates
- Certificat
